It has fundamentally changed the way in which chronic myeloid leukemia (CML) is treated, as BCR-ABL is a major driver of this malignancy [25]–[27]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.